We found a trend for a dose-response pattern with lower frequency of clinically manifest atherosclerotic disease across the number of vascular beds involved among carriers for these CCR2 variants (frequency of atherosclerosis presence among carriers vs. non-carriers: in no vascular bed 88.0% vs. 90.7%; in 1 vascular bed 10.5% vs. 9.1%; in 2 vascular beds 1.2% vs. 0.3%; in 3 vascular beds 0.3% vs 0.1%, in 4 vascular beds 0.03% vs 0%; OR from ordinal regression: 0.74, 95%CI: 0.54–0.97, p=0.01). This evidence concerns the gene CCR2 and atherosclerosis.